Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 8, 2019
Reporting Period: Single event date (October 8, 2019)
Business Context: The filing serves as a Regulation FD disclosure to announce upcoming presentations by company executives at industry conferences.
Key Financial Metrics
This Form 8-K is a disclosure of corporate events and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes or operational updates regarding the prior comparable period are reported in this filing. The document solely announces scheduled speaking engagements.
Guidance, Outlook, and Management Commentary
- Upcoming Presentations:
- 2nd Annual Advances in Immuno-Oncology USA Congress: RJ Tesi, M.D., Co-Founder and CEO, will present in San Diego on October 8 and October 9, 2019.
- World Immunotherapy Congress: RJ Tesi, M.D., and CJ Barnum, Ph.D., Director of Neuroscience, will present in Basel, Switzerland, from October 15 through October 17, 2019.
- Exhibit Status: The press release detailing these events is furnished as Exhibit 99.1 but is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the content of the press release (Exhibit 99.1) for specific details on the scientific data or updates to be presented at the conferences.
- Confirm the company's status as an emerging growth company (indicated as "Yes" in the filing).
- Monitor subsequent filings for any financial impact or strategic announcements resulting from these conference presentations.